212 related articles for article (PubMed ID: 26517132)
1. First Analysis of the Association Between CYP3A4/5, ABCB1 Genetic Polymorphisms and Oxcarbazepine Metabolism and Transport in Chinese Epileptic Patients with Oxcarbazepine Monotherapy and Bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YA; Zhou BT
J Pharm Pharm Sci; 2015; 18(3):256-65. PubMed ID: 26517132
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT
Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491
[TBL] [Abstract][Full Text] [Related]
3. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.
Yang X; Yan Y; Fang S; Zeng S; Ma H; Qian L; Chen X; Wei J; Gong Z; Xu Z
Medicine (Baltimore); 2019 Mar; 98(12):e14908. PubMed ID: 30896644
[TBL] [Abstract][Full Text] [Related]
4. Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy.
Shen C; Zhang B; Liu Z; Tang Y; Zhang Y; Wang S; Guo Y; Ding Y; Wang S; Ding M
Seizure; 2017 Oct; 51():102-106. PubMed ID: 28837897
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Lin WW; Li XW; Jiao Z; Zhang J; Rao X; Zeng DY; Lin XH; Wang CL
Eur J Clin Pharmacol; 2019 Mar; 75(3):381-392. PubMed ID: 30456415
[TBL] [Abstract][Full Text] [Related]
6. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
[TBL] [Abstract][Full Text] [Related]
7. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy.
Zhu X; Yun W; Sun X; Qiu F; Zhao L; Guo Y
Pharmacogenomics; 2014; 15(15):1867-79. PubMed ID: 25495409
[TBL] [Abstract][Full Text] [Related]
8. Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy.
Li RR; Sheng XY; Ma LY; Yao HX; Cai LX; Chen CY; Zhu SN; Zhou Y; Wu Y; Cui YM
Ther Drug Monit; 2016 Jun; 38(3):365-70. PubMed ID: 26818624
[TBL] [Abstract][Full Text] [Related]
9. Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis.
Lin WW; Wang CL; Jiao Z; Yu XL; Zhang J; Zhang WB; Lin RF; Lin S; Lin XH
Ther Drug Monit; 2019 Oct; 41(5):665-673. PubMed ID: 31033858
[TBL] [Abstract][Full Text] [Related]
10. Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world.
Li R; Zhou Q; Ou S; Wang Y; Li Y; Xia L; Pan S
Epilepsy Res; 2020 Oct; 166():106408. PubMed ID: 32679487
[TBL] [Abstract][Full Text] [Related]
11. Analysis of influencing factors on monohydroxylated derivative of oxcarbazepine plasma concentration in children with epilepsy.
Yao N; Huang S; Huang A; Song H
Eur J Clin Pharmacol; 2022 Oct; 78(10):1667-1675. PubMed ID: 36006433
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients.
Zhou Y; Wang X; Li H; Zhang J; Chen Z; Xie W; Zhang J; Li J; Zhou L; Huang M
Drug Metab Pharmacokinet; 2015 Aug; 30(4):282-7. PubMed ID: 26213157
[TBL] [Abstract][Full Text] [Related]
13. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
14. Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.
Liu L; Zhao L; Wang Q; Qiu F; Wu X; Ma Y
Eur J Clin Pharmacol; 2015 Nov; 71(11):1341-7. PubMed ID: 26303110
[TBL] [Abstract][Full Text] [Related]
15. Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
He XJ; Jian LY; He XL; Tang M; Wu Y; Xu YY; Sun XJ; Zhao LM
Epilepsia; 2014 Aug; 55(8):1301-6. PubMed ID: 24861996
[TBL] [Abstract][Full Text] [Related]
16. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population.
Ganesapandian M; Ramasamy K; Adithan S; Narayan SK
Indian J Pharmacol; 2019; 51(6):384-388. PubMed ID: 32029960
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Li X; Wei S; Wu H; Zhang Q; Zhao Z; Mei S; Feng W; Wu Y
Eur J Pediatr; 2023 Oct; 182(10):4509-4521. PubMed ID: 37493972
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.
Lu Q; Huang YT; Shu Y; Xu P; Xiang DX; Qu Q; Qu J
Medicine (Baltimore); 2018 Jul; 97(30):e11662. PubMed ID: 30045320
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of benign epilepsy of childhood with centrotemporal spikes in chinese children.
Liu MJ; Su XJ; Md XS; Wu GF; Zhang YQ; Gao L; Wang W; Liao JX; Wang H; Mai JN; Gao JY; Shu XM; Huang SP; Zhang L; Zou LP
Medicine (Baltimore); 2017 Jan; 96(4):e5623. PubMed ID: 28121917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
